Press Releases Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
45.72 ^USD	-0.59%		+3.96%	-24.02%

Apr. 23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
Apr. 22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	Apr. 22	BU
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K	Apr. 16	PU
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results	Apr. 11	BU
Innovative personalised immunotherapy approved for multiple myeloma	Apr. 08	AQ
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	Apr. 05	BU
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report	Mar. 20	AQ
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report	Mar. 19	BU
CARVYKTI (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma	Mar. 18	AQ
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma	Mar. 15	BU
Legend Biotech : Sponsor and FDA Briefing Books Released Prior to U.S. FDA Oncologic Drugs Advisory Committee Meeting for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) - Form 6-K	Mar. 13	PU
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights	Mar. 11	BU
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy	Feb. 26	AQ
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy	Feb. 23	BU
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results	Feb. 13	BU
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3	Jan. 03	BU
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	BU
Legend Biotech : Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) - Form 6-K	Dec. 21	PU
Legend Biotech : Performance-Based Equity Incentive Award for Chief Executive Officer - Form 6-K	Dec. 21	PU
Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN	Dec. 18	PR
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)	Dec. 11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Legend Biotech Corporation

Equities

LEGN

US52490G1022

Press Releases

Filters